CHMP Issues Positive Opinion Recommending DARZALEX (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- CHMP issued positive opinion for DARZALEX??in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
- Final decision from European Commission expected in the coming months
- Opinion based on data from Phase III CASSIOPEIA study
Attachment